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Since its introduction over a decade ago, acellular dermal matrix has become an integral part of expander/implant reconstruction. Currently, acellular dermal matrix is used in over 75 percent of immediate tissue expander breast reconstructions. 3 Marketed by a variety of manufacturers, this material is commonly placed as a sling between the inferior edge of the pectoralis muscle and the inframammary fold to provide support for the expander. Advocates of acellular dermal matrix in expander/implant reconstruction cite a number of purported benefits over traditional techniques, including the creation of aesthetically superior breast shapes by controlling implant position and improved tissue expansion dynamics, resulting in shorter expansion times and less patient discomfort. [5] [6] [7] [8] However, recent meta-analyses have reported greater risks of postoperative complications when acellular dermal matrix is used in expander/implant reconstruction, compared with total submuscular and dual-plane techniques. [9] [10] [11] These studies have noted higher rates of major infections, seromas, and reconstructive failures with acellular dermal matrix. Given the additional cost associated with use of acellular dermal matrix in expander-based reconstruction, assessing the potential benefits and risks of these materials has become particularly important in today's resourceconscious health care environment. 12 Despite the widespread use of acellular dermal matrix, there remains a paucity of high-quality research to critically evaluate its effectiveness. 13, 14 The majority of available studies have been limited by their small, single-center, single-surgeon patient populations and by their retrospective designs. Although advocates of acellular dermal matrix anecdotally report superior aesthetic results, there are few studies evaluating the effects of acellular dermal matrix on patient satisfaction and other patient-reported outcomes in expander/implant reconstruction. [15] [16] Using the multicenter Mastectomy Reconstruction Outcomes Consortium, this study sought to prospectively evaluate the effectiveness of acellular dermal matrix in implant-based, postmastectomy breast reconstruction, assessing associated risks and patient-reported outcomes.
PATIENTS AND METHODS
Patients were recruited as part of the Mastectomy Reconstruction Outcomes Consortium study, a prospective cohort study funded by the National Cancer Institute, involving 10 highvolume breast reconstruction centers and 58 surgeons across the United States and Canada. Institutional review board approval was obtained at all sites. Eligible patients were enrolled between 2012 and 2015 and included those undergoing tissue expander placement for immediate unilateral or bilateral reconstruction following mastectomy for breast cancer treatment or prophylaxis. All patients subsequently underwent expander exchange for saline-or silicone-filled reconstructive implants. In this analysis, all participants had 2-year follow-up data from the time of expander placement. Excluded were all patients undergoing delayed reconstruction, direct-to-implant procedures, autologous tissue techniques, or bilateral reconstruction with only unilateral acellular dermal matrix placement.
Study patients were divided into two cohorts: (1) those undergoing expander reconstruction with acellular dermal matrix, and (2) those undergoing expander reconstruction without acellular dermal matrix. After obtaining informed consent, patient demographic and clinical information was gathered from electronic medical records by the site coordinators and included age, body mass index, laterality (unilateral versus bilateral), indication for mastectomy (treatment versus prophylactic), mastectomy type (nipple-sparing, simple, or modified radical), smoking status, diabetes, lymph node management, adjuvant chemotherapy, and radiation therapy.
At 2 years after initial tissue expander placement, site coordinators collected clinical data, including complications, defined as adverse, surgery-related, postoperative events requiring additional treatment. Complications requiring rehospitalization or reoperation were designated as "major." Reconstructive failures (i.e., complications requiring implant removal) were also recorded. Finally, infections were subdivided into "all" and "major," with the former including all surgical-site infections (based on Centers for Disease Control and Prevention criteria) and the latter requiring intravenous antibiotics and/or reoperation.
Patient-reported outcomes were assessed using the previously validated BREAST-Q 17 and Numerical Pain Rating Scale, 18 which were completed preoperatively and at 1 week, 3 months, 1 year, and 2 years postoperatively. Domains of the BREAST-Q used for this analysis were Satisfaction with Breasts, Physical Well-being, Psychosocial Well-being and Sexual Well-being. Each domain score was obtained by transforming the scale item responses using the Q-Score software program. The transformed scores range from 0 to 100, with higher scores indicating greater satisfaction or quality of life. The Numerical Pain Rating Scale score was reported on a scale from 1 to 10, with higher scores indicating greater levels of pain. The BREAST-Q Physical Well-being subscale and Numerical Pain Rating Scale items were completed at all the five time points specified above. Items for all of the other domains for the BREAST-Q were completed preoperatively and at 1 year and 2 years postoperatively. Patients who experienced reconstructive failure were excluded from the final patient-reported outcome analysis.
Statistical Analysis
Clinical characteristics of patients were compared between acellular dermal matrix and nonacellular dermal matrix cohorts using the t test for continuous variables and chi-square tests for categorical variables. Rates of overall and specific postoperative complications were calculated as the proportion of patients with complications by acellular dermal matrix use cohorts. Complications were considered as patient-level outcomes throughout the analyses.
For the comparisons of 2-year complication between acellular dermal matrix use cohorts, separate mixed-effects logistic regression models were built for (1) any type of complication, (2) major complications, and (3) reconstructive failure. Each model included an indicator for acellular dermal matrix use, clinical characteristics, and random intercepts for centers (hospitals) and surgeons to account for between-center and between-surgeon variability. For the comparison of BREAST-Q Satisfaction with Breasts, Psychosocial Well-being, and Physical Well-being subscales, separate mixed-effects regression models were constructed, with dependent variables being the outcome measures at 2 years after reconstruction. Each model included an indicator for acellular dermal matrix use, clinical characteristics, and baseline values of the outcome measures as covariates, and random intercepts for centers (hospitals) to account for between-center variability. For the BREAST-Q Physical Well-being subscale and Numerical Pain Rating Scale, full longitudinal analyses were performed, with the dependent variables being the outcome measures collected across all the available time points. Each model included four time indicators (1 week, 3 months, 1 year, and 2 years after expander placement) and their interactions with acellular dermal matrix use. Clinical covariates and three sets of random intercepts-one for centers (hospitals), one for surgeons nested within centers, and one for patients nested within surgeons-were also included. This allowed for comparison between the two cohorts on the longitudinal change of repeated patient-reported outcome measures and accounted for between-patient, between-surgeon, and between-center variability.
Patient-reported outcomes scores at the 2-year postreconstruction time point were missing for approximately 40 percent of patients. To reduce potential bias, multiple imputations with chained equations were used to create 10 complete imputed data sets. The regression models specified above were fit for each imputed data set. The results were then combined using Rubin's rule. We reported adjusted odds ratios for complications and beta coefficients for patient-reported outcomes, with 95 percent confidence intervals and corresponding p values. All statistical analyses were performed with SAS 9.4 (SAS Institute, Inc., Cary, N.C.), and statistical significance was set at 0.05.
RESULTS
A total of 1297 patients undergoing immediate breast reconstruction with tissue expanders met inclusion criteria for this analysis. Acellular dermal matrix was used in 655 patients (50.5 percent), whereas 642 patients (49.5 percent) did not receive acellular dermal matrix during expander placement. Demographic and clinical characteristics for the two cohorts are summarized in Table 1 . Overall, the average patient age was 48.4 ± 10.4 years and the average body mass index 25.7 ± 5.3 kg/m 2 , with no significant differences in these variables between the patient cohorts. There were also no significant group differences in laterality (unilateral versus bilateral reconstructions). The median time from tissue expander placement to exchange was remarkably consistent: 5.4 months for acellular dermal matrix patients, compared with 5.6 months for those without acellular dermal matrix (p = 0.78). A greater proportion of acellular dermal matrix patients underwent mastectomy for prophylaxis, compared with the non-acellular dermal matrix group (14.0 percent versus 6.7 percent, respectively; p < 0.001). Patients with acellular dermal matrix underwent nipple-sparing mastectomies more frequently compared with the non-acellular dermal matrix cohort (21.8 percent versus 12 percent; p < 0.001). Fewer women with acellular dermal matrix had lymph node staging procedures (p < 0.001). The acellular dermal matrix cohort was less likely to undergo radiation therapy before or after reconstruction (p = 0.02) and was less likely to receive adjuvant Plastic and Reconstructive Surgery • December 2017 chemotherapy (p < 0.001), compared with nonacellular dermal matrix patients.
Acellular dermal matrix was used in 10 Mastectomy Reconstruction Outcomes Consortium centers and by 58 participating surgeons. Interestingly, most surgeons fell into one of two practice patterns: (1) those using acellular dermal matrix in the vast majority of their patients, or (2) those rarely or never using acellular dermal matrix. Of the 58 participants, 23 surgeons (49.6 percent) used acellular dermal matrix in over 80 percent of their immediate tissue expander reconstructions, whereas 15 surgeons (25.8 percent) used acellular dermal matrix in less than 20 percent of their cases, and of these, 11 surgeons did not use acellular dermal matrix at all. Only 20 surgeons (34.4 percent) relied on acellular dermal matrix more selectively, in 20 to 80 percent of their patients.
Two-year postoperative complication rates are listed in Table 2 . Although complication rates were generally higher in the acellular dermal matrix group, compared with the non-acellular dermal matrix cohort, these differences were not statistically significant for overall complications (27.9 percent versus 24.5 percent, respectively; p = 0.18), major complications (22.4 percent versus 15.7 percent, respectively; p = 0.052), wound infections (11.3 percent versus 9.5 percent; p = 0.11), or reconstructive failure (9.2 percent versus 5.8 percent; p = 0.13). In terms of specific complications, a higher wound dehiscence rate was observed in the acellular dermal matrix group (3.4 percent versus 0.8 percent; p = 0.02). The rate of wound infection requiring intravenous antibiotics or surgical intervention was also found to be higher in the acellular dermal matrix cohort (7.0 percent versus 4.5 percent for non-acellular dermal matrix patients; p = 0.045).
Results of the mixed effects logistic regression analyses for complications are listed in Table 3 . Although not statistically significant, the magnitude of the associated odds ratios suggests a trend toward higher risks within the acellular dermal matrix cohort for major complication and failure. Unadjusted patient-reported outcome scores are summarized in Table 4 . Before reconstruction, acellular dermal matrix and non-acellular dermal matrix cohorts reported similar levels of satisfaction with breasts, psychosocial well-being, physical well-being, and sexual well-being, and pain as measured by the BREAST-Q and the Numerical Pain Rating Scale.
Mixed-effects regression models for 2-year patient-reported outcomes are described in Table 5 . Controlling for demographic and clinical covariates, acellular dermal matrix compared to non-acellular dermal matrix patients had similar scores on BREAST-Q Satisfaction with Breasts (mean difference, −0.86; p = 0.59), Psychosocial Well-being (mean difference, 0.31; p = 0.85), and Sexual Well-being (mean difference, -1.72; p = 0.26) at 2 years (Table 5) .
The longitudinal analyses indicated that acellular dermal matrix had no significant effects on the change of BREAST-Q Physical Well-being or Numerical Pain Rating Scale over time, as shown by the absence of significant interactions between time and acellular dermal matrix (results not shown here). The final models were fit without the interaction terms ( Table 6 ) and showed that in both cohorts, physical well-being and pain increased significantly at 1 week after surgery and improved gradually thereafter. However, 2 years after reconstruction, both groups still experienced slightly higher pain and lower physical wellbeing, compared with their preoperative levels.
DISCUSSION
Since its introduction over a decade ago, acellular dermal matrix has revolutionized immediate tissue expander breast reconstruction, often supplanting more traditional total submuscular or dual-plane approaches. 3, 19 Although its proponents cite improved control of the implant pocket, accelerated tissue expansion dynamics, and superior aesthetic outcomes as rationale for its use, several studies have tempered this enthusiasm with reports of higher associated risks for postoperative complications compared with non-acellular dermal matrix techniques. 20 However, there is a lack of high-quality, prospective studies that comprehensively assess clinical outcomes. Few randomized controlled trials have been attempted, with the majority of published reports limited by retrospective designs and low patient numbers. 21 Among immediate tissue expander reconstruction patients, our analyses found that use of acellular dermal matrix had no significant effects on complications or patient-reported outcomes up to 2 years after the initial stage of reconstruction. This study used a multicenter prospective cohort design, enabling us to study 1297 patients from 10 participating centers and 58 plastic surgeons across the United States and Canada. The prospective nature and large sample size allowed us to control for a variety of potential confounding variables through regression analyses. These features constitute the major strengths of this study and support the generalizability of its findings. Plastic and Reconstructive Surgery • December 2017 BMI, body mass index; ADM, acellular dermal matrix; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection. *Defined as radiation therapy received after placement of the tissue expander but before exchange for the final implant.
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Several recent meta-analyses evaluating clinical outcomes in acellular dermal matrix-assisted breast reconstruction have reported higher overall complication rates with use of acellular dermal matrix in expander-based reconstruction. However, these studies have cited widely varying complication rates, ranging from 6 to 60 percent. 20 This wide variation may be explained by differences in study designs and by different definitions of what constitutes a complication. In our analysis, we found overall complication rates of 27.9 percent in the acellular dermal matrix cohort and 24.5 percent in the non-acellular dermal matrix group, which are consistent with those of previous reports. Controlling for a variety of potential confounding variables, acellular dermal matrix had no significant effects on complications in the regression analyses. Because surgical practices vary across sites and can impact outcomes, controlling for center effects was another important strength of this study.
Surgeons using acellular dermal matrix have clear preferences for particular brands of these products. However, in the current data analysis, we did not attempt to differentiate between acellular dermal matrix types. A number of manufacturers supply a large variety of acellular dermal matrix options, which vary in sterile preparation, need for rehydration, and shelf-lives. Several reports have attempted to assess differences in clinical complication rates between these products but have returned mixed results. Improved tissue expansion dynamics potentially resulting in accelerated rates of volume fill, fewer expansion procedures, and earlier exchange operations are among the commonly cited rationales for use of acellular dermal matrix in immediate breast reconstruction. 24 Our analysis found that the period from expander placement to exchange did not differ significantly between the two study cohorts, suggesting that acellular dermal matrix use may not confer a major time saving. Although this variable is arguably only a proxy measure of expansion rate and does not reflect actual differences in intraoperative fill volumes or numbers of expansion, it does indicate that acellular dermal matrix use may not facilitate faster completion times for reconstruction.
22,23
To date, the majority of published reports evaluating acellular dermal matrix-assisted breast reconstruction have focused on clinical outcomes, largely neglecting assessments of patient-reported outcomes. Only four studies were found to have used validated instruments. 8, 15, 21, 25 McCarthy and colleagues evaluated patient-reported outcomes using the BREAST-Q in a single-center, randomized, controlled trial comparing AlloDerm (LifeCell Corp., Branchburg, N.J.)-assisted immediate reconstruction with standard submuscular techniques. 22 This study reported no significant differences between acellular dermal matrix and non-acellular dermal matrix patients in postoperative physical well-being or pain. Although some studies have reported higher levels of satisfaction with the breasts following reconstruction in acellular dermal matrix cohorts, 16, 26 others have been unable to corroborate these findings. 27 The absence of significant acellular dermal matrix effects on expander-based reconstruction outcomes in our study raises an obvious question: Should we stop using acellular dermal matrix for these procedures? Given the number of studies supporting its use, our findings do not support abandonment of what many surgeons view as an extremely effective technique. However, these results do suggest that perhaps we need to be more selective in how and in whom we use acellular dermal matrix, given that it adds significantly to the cost of reconstruction. Previous authors have attempted to develop algorithms to identify patient populations in which acellular dermal matrix may prove beneficial, 28 but there remains a paucity of evidence-based selection criteria for use of this material in implant-based breast reconstruction. For example, although not reflected in our analysis, the use of acellular dermal matrix in nipple-sparing mastectomies might produce better outcomes. Additional prospective, multicenter research is needed to identify patient subgroups for which acellular dermal matrix may improve outcomes.
Despite its strengths, our study also has important limitations. As patients were not randomized to procedures with or without acellular dermal matrix, it remains conceivable that our results may be attributable to unknown demographic or clinical confounders. Although a randomized controlled trial design might have controlled for these unknown confounders, surgeons appear to have strong preferences for or against use of acellular dermal matrix in breast reconstruction, thus making a randomized controlled trial logistically challenging. In our analyses, there also remains a possibility of selection bias: perhaps surgeons preferentially used acellular dermal matrix for more difficult cases, thereby rendering a more conservative overall estimate of the effects of acellular dermal matrix. However, this latter possibility appears unlikely, given that the predominant number of surgeons in the study either used or avoided acellular dermal matrix in most or all of their cases.
Finally, nonresponse (dropout) rates are almost always a challenge in survey studies. For the Mastectomy Reconstruction Outcomes Consortium, we noted a 40 percent nonresponse rate at 2 years, despite systematic follow-up e-mails and phone calls from study staff to those with missing or incomplete surveys. Although we used multiple imputation statistical analyses to control for multiple variables, these methods were based on the assumption that missing data were independent of patient outcome (i.e., that nonresponders were no more or less likely to experience good or bad outcomes, compared to responders). Because we were unable to survey the nonresponders, the possibility of selection bias cannot be entirely excluded.
CONCLUSIONS
Acellular dermal matrix has become an integral component of immediate tissue expanderbased breast reconstruction. However, in a prospective, multicenter analysis comparing outcomes with and without acellular dermal matrix, we found no significant differences in postoperative complication rates. Furthermore, we did not observe any statistically significant acellular dermal matrix effects on patient-reported outcomes at 2 years. Given the costs of these materials, our results suggest a need for development
